Company
Investment-firm
Financing round
General
About Company
Industry
Sector :
Subsector :
founded date
founders
IPO status
Contacts
location
Contact Email
Phone number
Website URL
Similar Companies703
curative ventures
Curative Ventures is a venture capital firm that partners with biotech companies to develop innovative therapies.
Sector
Subsector
Location
count Of Investments
count Of Exists
H.I.G. BioHealth Partners
H.I.G. BioHealth Partners is a Miami-based venture capital firm.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
ALSA Ventures
ALSA Ventures is an international life science investor supporting biotechnology companies.
Sector
Subsector
Location
count Of Investments
WuXi Healthcare Ventures
WuXi Healthcare Ventures is a Chinese investment firm that helps life sciences companies develop transformative therapies.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Financials
Investments25
Latigo Biotherapeutics
The company develops non-opioid therapies for chronic pain, providing patients with addiction-free pain management options.
Sector
Subsector
Keywords
total rounds
total raised
Star Therapeutics
Star Therapeutics is a biotech company developing therapies for rare diseases.
Sector
Subsector
Location
total rounds
total raised
Kyverna Therapeutics
Kyverna Therapeutics is a company that is developing new therapies and cures for serious autoimmune diseases.
Sector
Subsector
Location
total rounds
total raised
Co-Investors
People
Founders1
Beth Seidenberg
Beth Seidenberg is a partner at Kleiner Perkins Caufield & Byers focused on life science investing. She works with entrepreneurs to develop companies with breakthrough technology for treating patients and improving health. Since joining KPCB in 2005, Beth has incubated five companies and serves on the board of directors of 3-V Biosciences, Armo Biosciences, Atara, Auxogyn, Breathe Technologies, Epizyme, iPierian, Redbrick Health and TESARO. Before joining KPCB, Beth was senior vice president of development and chief medical officer of Amgen, Inc. Earlier in her career, she was a senior executive in research and development at Bristol-Myers Squibb Co. and Merck & Co., Inc. Under her leadership, 10 innovative products were developed and marketed globally and achieved more than 40 regulatory approvals. Beth received her B.S. degree from Barnard College and her M.D. from the University of Miami. She completed her post-graduate training at Johns Hopkins University, George Washington University and the National Institutes of Health.
current job
Beth Seidenberg
Employee Profiles4
Activity
Recent News5
The graph reveals the ratio (%) of positive news articles in a chosen time range